Rabies News and Research

RSS

Saddle Up Safely campaign: Understanding how diseases of horse can affect humans

Although it is rare for humans to pick up a disease from a horse, education on the subject is the best source of prevention, and the Saddle Up Safely campaign addresses diseases, clinical signs and professional advice in a new booklet on this topic.

9 Mar 2010

Free online training Webinars to prepare nurses for continued relief efforts in Haiti launched

While disaster response is a highly technical and sensitive effort, the most qualified of disaster professionals require additional education or real-life experience to ensure that help is delivered effectively, safely and efficiently. To assist nursing professionals volunteering their services in Haiti, Chamberlain College of Nursing in cooperation with the Johnson & Johnson Campaign for Nursing's Future, will provide free online training Webinars hosted on the Gannett Healthcare Group's newly launched Haiti Web page to prepare nurses physically, mentally and culturally for the continued relief efforts.

6 Mar 2010

VSV has potential to be genetically modified to serve as anti-cancer agent

Vesicular stomatitis virus, or VSV, has long been a model system for studying and understanding the life cycle of negative-strand RNA viruses, which include viruses that cause influenza, measles and rabies.

10 Feb 2010

New vaccine to prevent malaria infection shown promise to protect young children

A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients - young children - against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa.

4 Feb 2010

Sinovac Biotech announces financial update, new joint ventures and developments

Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments.

21 Jan 2010

NanoViricides outlines its technology and current drug programs at Biotech Showcase conference

NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.

12 Jan 2010

Researchers advance in developing a vaccine against AIDS disease

Led by Matthias J. Schnell, Ph.D., director of the Jefferson Vaccine Center, the researchers found that a rabies virus-based vaccine administered to monkeys protected against the simian equivalent of the HIV virus (SIV). The data were published in the journal Vaccine.

15 Dec 2009

China's SFDA initiates quality investigation of Simcere Pharmaceutical Group subsidiary's rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") has initiated a comprehensive investigation into quality issues regarding human use rabies vaccine (vero cell) manufactured by Simcere's subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

3 Dec 2009

Jiangsu Yanshen Biological Technology Stock suspends production of all products

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that its subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen") has suspended production of all its products in order to conduct an internal inspection and improve its quality control systems.

2 Dec 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

25 Nov 2009

NIAID funds CCHI and IMVC programs to help identify new vaccines for emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $208 million to two programs that support research to better understand the human immune response to emerging and re-emerging infectious diseases, including those that may be introduced into a community through acts of bioterrorism.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

Schering-Plough to donate $200,000 and vaccine for rabies-control projects in India

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs. The company will donate $200,000 and rabies vaccine from Intervet/Schering-Plough as well as share expertise with partners to support successful implementation of the projects in ten villages surrounding Bangalore and Pune, India.

3 Nov 2009

Experts to develop effective surveillance system to monitor emerging infections at global level

Avian influenza (H5N1), rabies, plague, Bovine Spongiform Encephalopathy (BSE), and more recently swine flu (H1N1) are all examples of diseases that have made the leap from animals to humans.

8 Oct 2009

Peregrine Pharmaceuticals establishes a new Anti-Viral Research Group

Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.

7 Oct 2009

Phase 1 clinical trial to test safety and activity of human MAB launched in India

MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody (MAB) developed to neutralize the rabies virus.

1 Oct 2009

Single inoculation for rabies vaccination

...

21 Sep 2009

FluCide more effective than Tamiflu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.

15 Sep 2009

Exhibition on history of immunology to be presented at 2nd European Congress of Immunology

An exhibition entitled "The Birth of Immunology" during the 2nd European Congress of Immunology from13th to 16th September 2009 at the main foyer of the ICC in Berlin will offer insights into the fast-paced history of immunology. Immunology has promoted medical progress since the end of the 19th century like almost no other discipline.

8 Sep 2009